Search Results
You are looking at 1 - 9 of 9 items for
- Author: Jian Li x
- Refine by access: All content x
Search for other papers by Jian-Ting Ke in
Google Scholar
PubMed
Search for other papers by Mi Li in
Google Scholar
PubMed
Search for other papers by Shi-Qing Xu in
Google Scholar
PubMed
Search for other papers by Wen-Jian Zhang in
Google Scholar
PubMed
Search for other papers by Yong-Wei Jiang in
Google Scholar
PubMed
Search for other papers by Lan-yun Cheng in
Google Scholar
PubMed
Search for other papers by Li Chen in
Google Scholar
PubMed
Search for other papers by Jin-Ning Lou in
Google Scholar
PubMed
Search for other papers by Wei Wu in
Google Scholar
PubMed
The efficacy of gliquidone for the treatment of diabetic nephropathy was investigated by implanting micro-osmotic pumps containing gliquidone into the abdominal cavities of Goto-Kakizaki (GK) rats with diabetic nephropathy. Blood glucose, 24 h urinary protein, and 24 h urinary albumin levels were measured weekly. After 4 weeks of gliquidone therapy, pathological changes in the glomerular basement membrane (GBM) were examined using an electron microscope. Real-time PCR, western blotting, and immunohistochemistry were employed to detect glomerular expression of receptors for advanced glycation end products (RAGE) (AGER), protein kinase C β (PKCβ), and protein kinase A (PKA) as well as tubular expression of the albumin reabsorption-associated proteins: megalin and cubilin. Human proximal tubular epithelial cells (HK-2 cells) were used to analyze the effects of gliquidone and advanced glycation end products (AGEs) on the expression of megalin and cubilin and on the absorption of albumin. Gliquidone lowered blood glucose, 24 h urinary protein, and 24 h urinary albumin levels in GK rats with diabetic nephropathy. The level of plasma C-peptide increased markedly and GBM and podocyte lesions improved dramatically after gliquidone treatment. Glomerular expression of RAGE and PKCβ decreased after gliquidone treatment, while PKA expression increased. AGEs markedly suppressed the expression of megalin and cubulin and the absorption of albumin in HK-2 cells in vitro, whereas the expression of megalin and cubilin and the absorption of albumin were all increased in these cells after gliquidone treatment. In conclusion, gliquidone treatment effectively reduced urinary protein in GK rats with diabetic nephropathy by improving glomerular lesions and promoting tubular reabsorption.
Search for other papers by Li Juan He in
Google Scholar
PubMed
Search for other papers by Min Liang in
Google Scholar
PubMed
Search for other papers by Fan Fan Hou in
Google Scholar
PubMed
Search for other papers by Zhi Jian Guo in
Google Scholar
PubMed
Search for other papers by Di Xie in
Google Scholar
PubMed
Search for other papers by Xun Zhang in
Google Scholar
PubMed
There is evidence that inflammatory processes are involved in the development and/or progression of diabetic nephropathy. However, effective treatment for inflammation in the kidneys of diabetic is practically unknown. The rhizomes of Picrorhiza scrophulariiflora (PS) are a traditional medication long used to treat inflammatory diseases. The aim of the present study was to test the hypothesis that the ethanol extract of PS (EPS) may reduce inflammation in patients with diabetic kidneys. Streptozotocin-induced diabetic rats were randomly assigned to two groups treated with a gavage of either EPS or vehicle. A group of non-diabetic control rats was treated concurrently. Compared with vehicle-treated diabetic rats, EPS-treated animals displayed a significant decrease in renal macrophage infiltration and overexpression of chemokine (C-C motif) ligand 2 (CCL2) and TGFB1. This was associated with attenuation of the structural and functional abnormalities of early diabetic nephropathy, such as glomerular hypertrophy, mesangial expansion, and albuminuria. Administration of EPS significantly reduced NADPH oxidase-dependent superoxide generation and decreased expression of malondialdehyde and advanced oxidation protein products in diabetic kidney. These data suggest that EPS might improve diabetic nephropathy, probably through inhibition of redox-sensitive inflammation.
Search for other papers by Ya-Li Yang in
Google Scholar
PubMed
Search for other papers by Li-Rong Ren in
Google Scholar
PubMed
Search for other papers by Li-Feng Sun in
Google Scholar
PubMed
University of Chinese Academy of Sciences, Shenzhen, China
Search for other papers by Chen Huang in
Google Scholar
PubMed
Search for other papers by Tian-Xia Xiao in
Google Scholar
PubMed
Search for other papers by Bao-Bei Wang in
Google Scholar
PubMed
Search for other papers by Jie Chen in
Google Scholar
PubMed
Search for other papers by Brian A Zabel in
Google Scholar
PubMed
Search for other papers by Peigen Ren in
Google Scholar
PubMed
Search for other papers by Jian V Zhang in
Google Scholar
PubMed
Chemerin, a chemokine, plays important roles in immune responses, inflammation, adipogenesis, and carbohydrate metabolism. Our recent research has shown that chemerin has an inhibitory effect on hormone secretion from the testis and ovary. However, whether G protein-coupled receptor 1 (GPR1), the active receptor for chemerin, regulates steroidogenesis and luteolysis in the corpus luteum is still unknown. In this study, we established a pregnant mare serum gonadotropin-human chorionic gonadotropin (PMSG-hCG) superovulation model, a prostaglandin F2α (PGF2α) luteolysis model, and follicle and corpus luteum culture models to analyze the role of chemerin signaling through GPR1 in the synthesis and secretion of gonadal hormones during follicular/luteal development and luteolysis. Our results, for the first time, show that chemerin and GPR1 are both differentially expressed in the ovary over the course of the estrous cycle, with highest levels in estrus and metestrus. GPR1 has been localized to granulosa cells, cumulus cells, and the corpus luteum by immunohistochemistry (IHC). In vitro, we found that chemerin suppresses hCG-induced progesterone production in cultured follicle and corpus luteum and that this effect is attenuated significantly by anti-GPR1 MAB treatment. Furthermore, when the phosphoinositide 3-kinase (PI3K) pathway was blocked, the attenuating effect of GPR1 MAB was abrogated. Interestingly, PGF2α induces luteolysis through activation of caspase-3, leading to a reduction in progesterone secretion. Treatment with GPR1 MAB blocked the PGF2α effect on caspase-3 expression and progesterone secretion. This study indicates that chemerin/GPR1 signaling directly or indirectly regulates progesterone synthesis and secretion during the processes of follicular development, corpus luteum formation, and PGF2α-induced luteolysis.
Shanghai Key Laboratory of Endocrine Tumor, Division of Endocrinology and Metabolism, Shanghai Jiao-Tong University School of Medicine, Shanghai Institute of Endocrinology and Metabolism, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-Jin Hospital, 197 Rui-Jin 2nd Road, Shanghai 200025, People's Republic of China
Search for other papers by Chan-Juan Ma in
Google Scholar
PubMed
Shanghai Key Laboratory of Endocrine Tumor, Division of Endocrinology and Metabolism, Shanghai Jiao-Tong University School of Medicine, Shanghai Institute of Endocrinology and Metabolism, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-Jin Hospital, 197 Rui-Jin 2nd Road, Shanghai 200025, People's Republic of China
Search for other papers by Ai-Fang Nie in
Google Scholar
PubMed
Shanghai Key Laboratory of Endocrine Tumor, Division of Endocrinology and Metabolism, Shanghai Jiao-Tong University School of Medicine, Shanghai Institute of Endocrinology and Metabolism, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-Jin Hospital, 197 Rui-Jin 2nd Road, Shanghai 200025, People's Republic of China
Search for other papers by Zhi-Jian Zhang in
Google Scholar
PubMed
Shanghai Key Laboratory of Endocrine Tumor, Division of Endocrinology and Metabolism, Shanghai Jiao-Tong University School of Medicine, Shanghai Institute of Endocrinology and Metabolism, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-Jin Hospital, 197 Rui-Jin 2nd Road, Shanghai 200025, People's Republic of China
Search for other papers by Zhi-Guo Zhang in
Google Scholar
PubMed
Shanghai Key Laboratory of Endocrine Tumor, Division of Endocrinology and Metabolism, Shanghai Jiao-Tong University School of Medicine, Shanghai Institute of Endocrinology and Metabolism, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-Jin Hospital, 197 Rui-Jin 2nd Road, Shanghai 200025, People's Republic of China
Search for other papers by Li Du in
Google Scholar
PubMed
Shanghai Key Laboratory of Endocrine Tumor, Division of Endocrinology and Metabolism, Shanghai Jiao-Tong University School of Medicine, Shanghai Institute of Endocrinology and Metabolism, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-Jin Hospital, 197 Rui-Jin 2nd Road, Shanghai 200025, People's Republic of China
Search for other papers by Xiao-Ying Li in
Google Scholar
PubMed
Shanghai Key Laboratory of Endocrine Tumor, Division of Endocrinology and Metabolism, Shanghai Jiao-Tong University School of Medicine, Shanghai Institute of Endocrinology and Metabolism, Shanghai Clinical Center for Endocrine and Metabolic Diseases, Rui-Jin Hospital, 197 Rui-Jin 2nd Road, Shanghai 200025, People's Republic of China
Search for other papers by Guang Ning in
Google Scholar
PubMed
Genipin, a compound derived from Gardenia jasminoides Ellis fruits, has been used over the years in traditional Chinese medicine to treat symptoms of type 2 diabetes. However, the molecular basis for its antidiabetic effect has not been fully revealed. In this study, we investigated the effects of genipin on glucose uptake and signaling pathways in C2C12 myotubes. Our study demonstrates that genipin stimulated glucose uptake in a time- and dose-dependent manner. The maximal effect was achieved at 2 h with a concentration of 10 μM. In myotubes, genipin promoted glucose transporter 4 (GLUT4) translocation to the cell surface, which was observed by analyzing their distribution in subcellular membrane fraction, and increased the phosphorylation of insulin receptor substrate-1 (IRS-1), AKT, and GSK3β. Meanwhile, genipin increased ATP levels, closed KATP channels, and then increased the concentration of calcium in the cytoplasm in C2C12 myotubes. Genipin-stimulated glucose uptake could be blocked by both the PI3-K inhibitor wortmannin and calcium chelator EGTA. Moreover, genipin increases the level of reactive oxygen species and ATP in C2C12 myotubes. These results suggest that genipin activates IRS-1, PI3-K, and downstream signaling pathway and increases concentrations of calcium, resulting in GLUT4 translocation and glucose uptake increase in C2C12 myotubes.
Search for other papers by Sihan Lv in
Google Scholar
PubMed
Translational Medical Center for Stem Cell Therapy & Institute for Regenerative Medicine, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China
Search for other papers by Xinchen Qiu in
Google Scholar
PubMed
Translational Medical Center for Stem Cell Therapy & Institute for Regenerative Medicine, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China
Search for other papers by Jian Li in
Google Scholar
PubMed
Search for other papers by Jinye Liang in
Google Scholar
PubMed
Search for other papers by Weida Li in
Google Scholar
PubMed
Search for other papers by Chao Zhang in
Google Scholar
PubMed
Search for other papers by Zhen-Ning Zhang in
Google Scholar
PubMed
Search for other papers by Bing Luan in
Google Scholar
PubMed
Hormonal signals help to maintain glucose and lipid homeostasis in the liver during the periods of fasting. Glucagon, a pancreas-derived hormone induced by fasting, promotes gluconeogenesis through induction of intracellular cAMP production. Glucagon also stimulates hepatic fatty acid oxidation but the underlying mechanism is poorly characterized. Here we report that following the acute induction of gluconeogenic genes Glucose 6 phosphatase (G6Pase) and Phosphoenolpyruvate carboxykinase (Pepck) expression through cAMP-response element-binding protein (CREB), glucagon triggers a second delayed phase of fatty acid oxidation genes Acyl-coenzyme A oxidase (Aox) and Carnitine palmitoyltransferase 1a (Cpt1a) expression via extracellular cAMP. Increase in extracellular cAMP promotes PPARα activity through direct phosphorylation by AMP-activated protein kinase (AMPK), while inhibition of cAMP efflux greatly attenuates Aox and Cpt1a expression. Importantly, cAMP injection improves lipid homeostasis in fasted mice and obese mice, while inhibition of cAMP efflux deteriorates hepatic steatosis in fasted mice. Collectively, our results demonstrate the vital role of glucagon-stimulated extracellular cAMP in the regulation of hepatic lipid metabolism through AMPK-mediated PPARα activation. Therefore, strategies to improve cAMP efflux could serve as potential new tools to prevent obesity-associated hepatic steatosis.
Search for other papers by Lei Li in
Google Scholar
PubMed
Search for other papers by Ping Ma in
Google Scholar
PubMed
Search for other papers by Chen Huang in
Google Scholar
PubMed
Search for other papers by Yongjun Liu in
Google Scholar
PubMed
Search for other papers by Ye Zhang in
Google Scholar
PubMed
Search for other papers by Chen Gao in
Google Scholar
PubMed
Search for other papers by Tianxia Xiao in
Google Scholar
PubMed
Search for other papers by Pei-Gen Ren in
Google Scholar
PubMed
Search for other papers by Brian A Zabel in
Google Scholar
PubMed
Laboratory for Reproductive Health, Palo Alto Institute for Research and Education, Guangdong Key Laboratory of Nanomedicine, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China
Search for other papers by Jian V Zhang in
Google Scholar
PubMed
The novel adipokine chemerin plays a role in the regulation of lipid and carbohydrate metabolism, and recent reports of elevated chemerin levels in polycystic ovarian syndrome and preeclampsia have pointed to an emerging role of chemerin in reproduction. We hypothesised that chemerin, like other adipokines, may function to regulate male gonadal steroidogenesis. In this study, we show that chemerin and its three receptors chemokine-like receptor 1 (CMKLR1), G-protein-coupled receptor 1 (GPR1) and chemokine (C-C motif) receptor-like 2 were expressed in male reproductive tracts, liver and white adipose tissue. CMKLR1 and GPR1 proteins were localised specifically in the Leydig cells of human and rat testes by immunohistochemistry. The expression of chemerin and its receptors in rat testes was developmentally regulated and highly expressed in Leydig cells. In vitro treatment with chemerin suppressed the human chorionic gonadotropin (hCG)-induced testosterone production from primary Leydig cells, which was accompanied by the inhibition of 3β-hydroxysteroid dehydrogenase gene and protein expression. The hCG-activated p44/42 MAPK (Erk1/2) pathway in Leydig cells was also inhibited by chemerin cotreatment. Together, these data suggest that chemerin is a novel regulator of male gonadal steroidogenesis.
Department of Nutrition and Food Hygiene, MOE Key Lab of Environment and Health, School of Environmental Science and Public Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, People's Republic of China
Search for other papers by Shibin Ding in
Google Scholar
PubMed
Search for other papers by Ying Fan in
Google Scholar
PubMed
Search for other papers by Nana Zhao in
Google Scholar
PubMed
Search for other papers by Huiqin Yang in
Google Scholar
PubMed
Search for other papers by Xiaolei Ye in
Google Scholar
PubMed
Search for other papers by Dongliang He in
Google Scholar
PubMed
Search for other papers by Xin Jin in
Google Scholar
PubMed
Search for other papers by Jian Liu in
Google Scholar
PubMed
Search for other papers by Chong Tian in
Google Scholar
PubMed
Search for other papers by Hongyu Li in
Google Scholar
PubMed
Search for other papers by Shunqing Xu in
Google Scholar
PubMed
Department of Nutrition and Food Hygiene, MOE Key Lab of Environment and Health, School of Environmental Science and Public Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, People's Republic of China
Search for other papers by Chenjiang Ying in
Google Scholar
PubMed
Epidemiological findings on the association between bisphenol A (BPA, 2,2-bis-(4-hydroxyphenyl)propane) exposure and type 2 diabetes mellitus (T2DM) are paradoxical. In animal studies, BPA has been shown to disrupt pancreatic function and blood glucose homeostasis even at a reference ‘safe’ level during perinatal period. In this study, we explored the effects of long-term paternal exposure to a ‘safe’ level of BPA on parents themselves and their offspring. Adult male genitor rats fed with either standard chow diet (STD) or high-fat diet (HFD) were treated respectively with either vehicle or BPA (50 μg/kg per day) for 35 weeks. The male rats treated with vehicle or BPA for 21 weeks were then used as sires, and the adult female rats were fed with STD during the gestation and lactation. Offspring rats were weaned on postnatal day 21 and fed with STD in later life. Metabolic parameters were recorded on the adult male rats and their adult offspring. BPA exposure disrupted glucose homeostasis and pancreatic function, and HFD aggravated these adverse effects. However, BPA exposure did not alter body weight, body fat percentage, or serum lipid. In addition, the paternal BPA exposure did not cause adverse reproductive consequence or metabolic disorder in the adult offspring. Our findings indicate that chronic exposure to a predicted ‘safe’ dose of BPA contributes to glucose metabolic disorders, and that HFD aggravates these adverse effects in paternal rats.
Biotecan Medical Diagnostics Co., Ltd, Zhangjiang Center for Translational Medicine, Shanghai, China
Search for other papers by Wang-Yang Xu in
Google Scholar
PubMed
Search for other papers by Yan Shen in
Google Scholar
PubMed
Search for other papers by Houbao Zhu in
Google Scholar
PubMed
Search for other papers by Junhui Gao in
Google Scholar
PubMed
Search for other papers by Chen Zhang in
Google Scholar
PubMed
Search for other papers by Lingyun Tang in
Google Scholar
PubMed
Search for other papers by Shun-Yuan Lu in
Google Scholar
PubMed
Search for other papers by Chun-Ling Shen in
Google Scholar
PubMed
Search for other papers by Hong-Xin Zhang in
Google Scholar
PubMed
Search for other papers by Ziwei Li in
Google Scholar
PubMed
Search for other papers by Peng Meng in
Google Scholar
PubMed
Search for other papers by Ying-Han Wan in
Google Scholar
PubMed
Search for other papers by Jian Fei in
Google Scholar
PubMed
Shanghai Research Center for Model Organisms, Shanghai, China
Model Organism Division, E-Institutes of Shanghai Universities, Shanghai, China
Search for other papers by Zhu-Gang Wang in
Google Scholar
PubMed
Obesity and type 2 diabetes (T2D) are both complicated endocrine disorders resulting from an interaction between multiple predisposing genes and environmental triggers, while diet and exercise have key influence on metabolic disorders. Previous reports demonstrated that 2-aminoadipic acid (2-AAA), an intermediate metabolite of lysine metabolism, could modulate insulin secretion and predict T2D, suggesting the role of 2-AAA in glycolipid metabolism. Here, we showed that treatment of diet-induced obesity (DIO) mice with 2-AAA significantly reduced body weight, decreased fat accumulation and lowered fasting glucose. Furthermore, Dhtkd1−/− mice, in which the substrate of DHTKD1 2-AAA increased to a significant high level, were resistant to DIO and obesity-related insulin resistance. Further study showed that 2-AAA induced higher energy expenditure due to increased adipocyte thermogenesis via upregulating PGC1α and UCP1 mediated by β3AR activation, and stimulated lipolysis depending on enhanced expression of hormone-sensitive lipase (HSL) through activating β3AR signaling. Moreover, 2-AAA could alleviate the diabetic symptoms of db/db mice. Our data showed that 2-AAA played an important role in regulating glycolipid metabolism independent of diet and exercise, implying that improving the level of 2-AAA in vivo could be developed as a strategy in the treatment of obesity or diabetes.
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
Search for other papers by Lei Du in
Google Scholar
PubMed
Search for other papers by Yang Wang in
Google Scholar
PubMed
Search for other papers by Cong-Rong Li in
Google Scholar
PubMed
Search for other papers by Liang-Jian Chen in
Google Scholar
PubMed
Search for other papers by Jin-Yang Cai in
Google Scholar
PubMed
Search for other papers by Zheng-Rong Xia in
Google Scholar
PubMed
Search for other papers by Wen-Tao Zeng in
Google Scholar
PubMed
Search for other papers by Zi-Bin Wang in
Google Scholar
PubMed
Search for other papers by Xi-Chen Chen in
Google Scholar
PubMed
Search for other papers by Fan Hu in
Google Scholar
PubMed
Animal Core Facility, Nanjing Medical University, Nanjing, Jiangsu, China
Search for other papers by Dong Zhang in
Google Scholar
PubMed
Search for other papers by Xiao-Wei Xing in
Google Scholar
PubMed
Search for other papers by Zhi-Xia Yang in
Google Scholar
PubMed
Polycystic ovarian syndrome (PCOS) is a major severe ovary disorder affecting 5–10% of reproductive women around the world. PCOS can be considered a metabolic disease because it is often accompanied by obesity and diabetes. Brown adipose tissue (BAT) contains abundant mitochondria and adipokines and has been proven to be effective for treating various metabolic diseases. Recently, allotransplanted BAT successfully recovered the ovarian function of PCOS rat. However, BAT allotransplantation could not be applied to human PCOS; the most potent BAT is from infants, so voluntary donors are almost inaccessible. We recently reported that single BAT xenotransplantation significantly prolonged the fertility of aging mice and did not cause obvious immunorejection. However, PCOS individuals have distinct physiologies from aging mice; thus, it remains essential to study whether xenotransplanted rat BAT can be used for treating PCOS mice. In this study, rat-to-mouse BAT xenotransplantation, fortunately, did not cause severe rejection reaction, and significantly recovered ovarian functions, indicated by the recovery of fertility, oocyte quality, and the levels of multiple essential genes and kinases. Besides, the blood biochemical index, glucose resistance, and insulin resistance were improved. Moreover, transcriptome analysis showed that the recovered PCOS F0 mother following BAT xenotransplantation could also benefit the F1 generation. Finally, BAT xenotransplantation corrected characteristic gene expression abnormalities found in the ovaries of human PCOS patients. These findings suggest that BAT xenotransplantation could be a novel therapeutic strategy for treating PCOS patients.
